Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 1/2 Study of REGN5093 M114 (METxMET Antibody Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer
NCT Number:
NCT04982224
Phase:
I/II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lung
Study Objectives:
To assess the safety, tolerability and pharmacokinetics (PK) of the antibody drug
conjugate (ADC) REGN5093-M114 in order to determine an MTD and/or define the
recommended phase 2 dose (RP2D) of REGN5093-M114 in patients with mesenchymal epithelial transition factor (MET) overexpressing non-small cell lung cancer (NSCLC). The PK of the ADC REGN5093-M114 includes the assessment of REGN5093-M114, total antibody, and payload M24 concentrations. To assess preliminary anti-tumor activity of REGN5093-M114 in MET overexpressed
NSCLC as measured by the objective response rate (ORR).
Study Documents
(MUSC NetID required for document access)